Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2C | P18825 | 1/20 | 0.55 |
| ▸ | MELK | Q14680 | 1/20 | 0.54 |
| ▸ | PRKD1 | Q15139 | 9/20 | 0.48 |
| ▸ | AGXT | P21549 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | HCK | P08631 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12692679 | 0.78 | ADORA2A (0.54) | JAK2 | |
| SCHEMBL3620897 | 0.76 | ADRA2C (0.55) | ADRA2CMELKAGXTJAK2FLT3 | |
| SCHEMBL1792824 | 0.75 | MELK (0.46) | ADRA2CMELKPRKD1AGXTLCK | |
| SCHEMBL1792823 | 0.75 | MELK (0.46) | ADRA2CMELKPRKD1AGXTLCK | |
| SCHEMBL3580409 | 0.75 | ADRA2C (0.54) | ADRA2CMELKAGXTJAK2FLT3 | |
| SCHEMBL5534704 | 0.74 | MELK (0.47) | MELKPRKD1JAK2FLT3MAP4K1 | |
| SCHEMBL30574697 | 0.74 | ADRA2C (0.49) | ADRA2CMELKPRKD1AGXT | |
| SCHEMBL30108214 | 0.73 | HTR1A (0.64) | ADRA2CAGXT | |
| SCHEMBL448110 | 0.72 | ADRA2C (1.00) | ADRA2CAGXT | |
| SCHEMBL28977172 | 0.72 | MELK (0.86) | MELKPRKD1JAK2FLT3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2470539-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | Array Biopharma, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011025951-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | ARRAY BIOPHARMA INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157451-A1 | RAF INHIBITOR COMPOUNDS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | ADRA2C 3557/4885MELK 324/4885PRKD1 430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.